Key Highlights
- Longeveron (Nasdaq: LGVN) reported that topline Phase 2b ELPIS II results for laromestrocel in infants with hypoplastic left heart syndrome missed the primary endpoint.
- Right ventricular ejection fraction improvement at Month 12 was -0.7 percentage points versus placebo, with a p-value of 0.8336.
- The trial showed a favorable safety profile with no new safety signals.
- Longeveron (Nasdaq: LGVN) is exploring strategic Options and implementing cost containment measures.
ELPIS II Fails to Separate From Placebo
Longeveron (Nasdaq: LGVN) reported topline results from its Phase 2b ELPIS II trial evaluating laromestrocel in infants with hypoplastic left heart syndrome. The trial missed its primary endpoint of right ventricular ejection fraction improvement at Month 12, recording a difference of -0.7 percentage points versus placebo, with a p-value of 0.8336, indicating no statistically significant benefit.
Safety Profile Remains Favorable
Despite the efficacy miss, Longeveron (Nasdaq: LGVN) noted that laromestrocel demonstrated a favorable safety profile in the trial, with no new safety signals identified in infants with this rare and severe congenital heart condition.
Company Reviews Strategic Options
Following the results, Longeveron (Nasdaq: LGVN) said it is exploring all strategic options to maximize Shareholder value and is implementing cost containment measures as it reassesses its pipeline priorities in light of the ELPIS II outcome.
What did the ELPIS II trial evaluate?
Laromestrocel in infants with hypoplastic left heart syndrome, measuring right ventricular ejection fraction improvement at Month 12.
Did the trial meet its primary endpoint?
No. The difference versus placebo was -0.7 percentage points, with a p-value of 0.8336.
What is Longeveron doing in response?
The company is exploring strategic options to maximize shareholder value and implementing cost containment measures.






Please wait processing your request...